163 related articles for article (PubMed ID: 11430476)
1. Comparison of the angiotensin II type 1-receptor antagonist YM358 and the angiotensin-converting enzyme inhibitor enalapril in rats with cardiac volume overload.
Tokioka-Akagi T; Fujimori A; Shibasaki M; Inagaki O; Yanagisawa I
Jpn J Pharmacol; 2001 May; 86(1):79-85. PubMed ID: 11430476
[TBL] [Abstract][Full Text] [Related]
2. Effects of YM358, an angiotensin II type 1 (AT1) receptor antagonist, and enalapril on blood pressure and vasoconstriction in two renal hypertension models.
Tokioka T; Shibasaki M; Fujimori A; Matsuda-Satoh Y; Uchida W; Inagaki O; Yanagisawa I
Biol Pharm Bull; 2000 Feb; 23(2):174-81. PubMed ID: 10706380
[TBL] [Abstract][Full Text] [Related]
3. The renin-angiotensin system and volume overload-induced cardiac hypertrophy in rats. Effects of angiotensin converting enzyme inhibitor versus angiotensin II receptor blocker.
Ruzicka M; Yuan B; Harmsen E; Leenen FH
Circulation; 1993 Mar; 87(3):921-30. PubMed ID: 8443912
[TBL] [Abstract][Full Text] [Related]
4. Role of angiotensin in pressure overload-induced hypertrophy in rats: effects of angiotensin-converting enzyme inhibitors, an AT1 receptor antagonist, and surgical reversal.
Mohabir R; Young SD; Strosberg AM
J Cardiovasc Pharmacol; 1994 Feb; 23(2):291-9. PubMed ID: 7511760
[TBL] [Abstract][Full Text] [Related]
5. Effects of angiotensin II type 1 receptor antagonist, YM358, on cardiac hypertrophy and dysfunction after myocardial infarction in rats.
Oka-Akagi T; Fujimori A; Shibasaki M; Matsuda-Satoh Y; Inagaki O; Yanagisawa I
Biol Pharm Bull; 2002 Jul; 25(7):857-60. PubMed ID: 12132657
[TBL] [Abstract][Full Text] [Related]
6. Effects of enalapril versus losartan on regression of volume overload-induced cardiac hypertrophy in rats.
Ruzicka M; Yuan B; Leenen FH
Circulation; 1994 Jul; 90(1):484-91. PubMed ID: 8026035
[TBL] [Abstract][Full Text] [Related]
7. The renin-angiotensin system and volume overload-induced changes in cardiac collagen and elastin.
Ruzicka M; Keeley FW; Leenen FH
Circulation; 1994 Oct; 90(4):1989-96. PubMed ID: 7923689
[TBL] [Abstract][Full Text] [Related]
8. Chronic low-dose treatment with enalapril induced cardiac regression of left ventricular hypertrophy.
Makino N; Sugano M; Hata T; Taguchi S; Yanaga T
Mol Cell Biochem; 1996; 163-164():239-45. PubMed ID: 8974063
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II type-1 receptor antagonist as well as angiotensin converying enzyme inhibitor attenuates the development of heart failure in aortocaval fistula rats.
Nishikimi T; Tani T; Ohmura T; Yamagishi H; Yanagi S; Yoshiyama M; Toda I; Teragaki M; Akioka K; Takeuchi K
Jpn Circ J; 1995 Nov; 59(11):754-61. PubMed ID: 8747765
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profile of YM358, a novel nonpeptide angiotensin AT1 receptor antagonist.
Shibasaki M; Fujimori A; Takanashi M; Kusayama T; Tokioka T; Satoh Y; Okazaki T; Uchida W; Inagaki O; Yanagisawa I
Eur J Pharmacol; 1997 Sep; 335(2-3):167-73. PubMed ID: 9369370
[TBL] [Abstract][Full Text] [Related]
11. Differential subcellular actions of ACE inhibitors and AT(1) receptor antagonists on cardiac remodeling induced by chronic inhibition of NO synthesis in rats.
Sanada S; Kitakaze M; Node K; Takashima S; Ogai A; Asanuma H; Sakata Y; Asakura M; Ogita H; Liao Y; Fukushima T; Yamada J; Minamino T; Kuzuya T; Hori M
Hypertension; 2001 Sep; 38(3):404-11. PubMed ID: 11566913
[TBL] [Abstract][Full Text] [Related]
12. Antihypertensive effect of repeatedly administered YM358, an angiotensin AT1-receptor antagonist, in stroke-prone spontaneously hypertensive rats.
Yamaguchi N; Fujimoto K; Fujii T; Suzuki T; Kawashima K
Jpn J Pharmacol; 1997 Jan; 73(1):83-91. PubMed ID: 9032137
[TBL] [Abstract][Full Text] [Related]
13. Regional hemodynamic effects of candesartan cilexetil (TCV-116), an angiotensin II AT1-receptor antagonist, in conscious spontaneously hypertensive rats.
Kanagawa R; Wada T; Sanada T; Ojima M; Inada Y
Jpn J Pharmacol; 1997 Mar; 73(3):185-90. PubMed ID: 9127812
[TBL] [Abstract][Full Text] [Related]
14. Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats.
Carraway JW; Park S; McCune SA; Holycross BJ; Radin MJ
J Cardiovasc Pharmacol; 1999 Mar; 33(3):451-60. PubMed ID: 10069682
[TBL] [Abstract][Full Text] [Related]
15. Chronic enalapril treatment increases transient outward potassium current in cardiomyocytes isolated from right ventricle of spontaneously hypertensive rats.
Rodrigues Junior LF; de Azevedo Carvalho AC; Pimentel EB; Mill JG; Nascimento JH
Naunyn Schmiedebergs Arch Pharmacol; 2017 Mar; 390(3):225-234. PubMed ID: 27915452
[TBL] [Abstract][Full Text] [Related]
16. Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR.
Nunez E; Hosoya K; Susic D; Frohlich ED
Hypertension; 1997 Jan; 29(1 Pt 2):519-24. PubMed ID: 9039153
[TBL] [Abstract][Full Text] [Related]
17. Differential suppression of pressure-overload cardiac and aortic hypertrophy in rats by angiotensin-converting enzyme inhibitors.
Wang DQ; Kakizoe E; Kobayashi Y; Shimoura K; Okunishi H
Jpn J Pharmacol; 1999 Aug; 80(4):333-42. PubMed ID: 10496334
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II type 2 receptor blockade partially negates antihypertrophic effects of type 1 receptor blockade on pressure-overload rat cardiac hypertrophy.
Mukawa H; Toki Y; Miyazaki Y; Matsui H; Okumura K; Ito T
Hypertens Res; 2003 Jan; 26(1):89-95. PubMed ID: 12661917
[TBL] [Abstract][Full Text] [Related]
19. Relevance of blockade of cardiac and circulatory angiotensin-converting enzyme for the prevention of volume overload-induced cardiac hypertrophy.
Ruzicka M; Leenen FH
Circulation; 1995 Jan; 91(1):16-9. PubMed ID: 7805197
[TBL] [Abstract][Full Text] [Related]
20. Divergent effects of angiotensin-converting enzyme inhibition and angiotensin II-receptor antagonism on myocardial cellular proliferation and collagen deposition after myocardial infarction in rats.
Taylor K; Patten RD; Smith JJ; Aronovitz MJ; Wight J; Salomon RN; Konstam MA
J Cardiovasc Pharmacol; 1998 May; 31(5):654-60. PubMed ID: 9593063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
